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Abstract
Background: Eukaryotic transcription activators normally consist of a sequence-specific DNA-binding domain (DBD)
and a transcription activation domain (AD). While many sequence patterns and motifs have been defined for DBDs,
ADs do not share easily recognizable motifs or structures.
Results: We report herein that the N-terminal domain of yeast valyl-tRNA synthetase can function as an AD when
fused to a DNA-binding protein, LexA, and turn on reporter genes with distinct LexA-responsive promoters. The
transcriptional activity was mainly attributed to a five-residue peptide, WYDWW, near the C-terminus of the N
domain. Remarkably, the pentapeptide per se retained much of the transcriptional activity. Mutations which
substituted tryptophan residues for both of the non-tryptophan residues in the pentapeptide (resulting in W5)
significantly enhanced its activity (~1.8-fold), while mutations which substituted aromatic residues with alanine
residues severely impaired its activity. Accordingly, a much more active peptide, pentatryptophan (W7), was
produced, which elicited ~3-fold higher activity than that of the native pentapeptide and the N domain. Further
study indicated that W7 mediates transcription activation through interacting with the general transcription factor,
TFIIB.
Conclusions: Since W7 shares no sequence homology or features with any known transcription activators, it may
represent a novel class of AD.
Background
Eukaryotic transcriptional activators that stimulate tran-
scription initiation of a particular set of target genes
usually consist of a sequence-specific DNA-binding
domain (DBD) and a transcription activation domain
(AD). The DBD targets these activators to a specific loca-
tion in the promoter region of a gene, and the AD med-
iates transcription initiation by recruiting gene-specific
factors, chromatin-remodeling factors, mediator com-
plexes, and general transcription factors [1,2]. DBDs are
classified into several distinct patterns or motifs accord-
ing to their sequences and structural similarities. In con-
trast, ADs do not share significant sequence homologies,
and therefore no specific motif has been defined. Despite
this, several classes of ADs with distinctive sequence fea-
tures were identified, including acidic activators [3], glu-
tamine-rich activators [4], and proline-rich activators [5].
While an increasing number of transcriptional activators
have been identified, the direct targets or interacting
partners of most transcriptional activators and the
detailed mechanisms through which these interacting
partners induce transcription initiation remain largely
unknown. To date, only a few protein factors have been
explicitly identified as direct targets of transcriptional
activators, including the TATA box-binding protein
(TBP), TFIIB, TFIIH, and a few others [6].
One of the earliest and best-studied models for tran-
scriptional regulation in eukaryotes is that of yeast Gal4,
which is involved in regulating galactose metabolism in
response to changes in the concentration of the carbo-
hydrate [2,7]. The Gal4 system (also known as the GAL
regulon) consists of four structural (GAL1, GAL2, GAL7,
and GAL10) and three regulatory (GAL3, GAL4, and
GAL80) genes. Protein products of the structural genes
are required for transport and metabolism of galactose,
and protein products of the regulatory genes control
expression of the structural genes. Gal4 is an acidic
transcriptional activator comprised of two functionally
independent domains: an N-terminal sequence-specific
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DBD and a C-terminal AD. Induction of the Gal4-
responsive genes by galactose is mediated through the
specific binding of the Gal4-DBD to an upstream acti-
vating sequence in their promoter regions and subse-
quent recruitment of the general transcription apparatus
by the Gal4-AD. Under non-inducing conditions in the
absence of galactose, Gal4 activity is repressed by the
interaction of Gal80 with the Gal4-AD [8,9]. Under
inducing conditions when galactose is present, the
repressor, Gal80, is taken away by Gal3 from the Gal4-
AD, which is then able to recruit the transcription
machinery and initiate transcription [10].
In prokaryotes, there are typically 20 aminoacyl-tRNA
synthetases, one for each amino acid [11-14]. In eukar-
yotes, protein synthesis occurs in the cytoplasm, and
also in organelles, such as mitochondria and chloro-
plasts [15]. Thus, eukaryotes, such as yeast, commonly
have two genes that encode distinct sets of proteins for
each aminoacylation activity, one localized in the cyto-
plasm and the other in the mitochondria. However, in
some cases, the cytoplasmic and mitochondrial forms of
a tRNA synthetase with a given amino acid specificity
are encoded by the same nuclear gene through alterna-
tive initiation of translation, examples of which include
ALA1 (which codes for alanyl-tRNA synthetase) [16],
GRS1 (which codes for glycyl-tRNA synthetase) [17],
HTS1 (which codes for histidyl-tRNA synthetase)
[18], and VAS1 (which codes for valyl-tRNA synthetase
(ValRS)) [19]. Because the two isoforms are essentially
generated from the same open reading frame, they have
the same polypeptide sequence, except for a short
sequence attached to the amino-terminus of the mito-
chondrial precursor that functions as a mitochondrial
targeting signal. As a consequence, the two isoforms
cannot be substituted for each other in vivo.
Many eukaryotic cytoplasmic tRNA synthetases con-
tain an amino- or carboxyl-terminal polypeptide exten-
sion, which is absent from their bacterial counterparts
[20]. These extensions are generally rich in lysine resi-
dues and capable of non-specifically binding to RNA.
A well-studied example is the appended domain (Ad) of
yeast glutaminyl-tRNA synthetase (GlnRS), which binds
unfractionated yeast tRNAs, single-stranded RNA, and
pseudoknot RNA with comparable affinities, with Kd
values of around 0.6 μM [21,22]. Many other examples
were also identified, such as the carboxyl-terminal
domain of rice methionyl-tRNA synthetase [23] and the
amino-terminal domain of mammalian lysyl-tRNA
synthetase [24]. In addition to RNA binding, the Ads of
some tRNA synthetases were found to participate in
protein-protein interactions, such as those of yeast glu-
tamyl- and methionyl-tRNA synthetases (GluRS and
MetRS) [25] and mammalian ValRS [26]. However,
more generally, the exact role of the Ad in the biological
functions of this family of enzymes remains elusive.
Recently, it was found that many of these Ads contain
one or several classical nuclear localization signals [27]
which are believed to play a role in the nuclear importa-
tion of these otherwise “cytoplasmic” proteins. Even
more exciting are the findings that several tRNA synthe-
tases from both prokaryotes and eukaryotes take part in
functions unrelated to aminoacylation, including roles in
mitochondrial RNA splicing, transcriptional and transla-
tional regulation, cytokine-like activity, and amino acid
biosynthesis [28,29].
As with many known yeast tRNA synthetases, the
cytoplasmic form of yeast ValRS also contains an
amino-terminal polypeptide extension. While the Ad of
mammalian ValRS was shown to interact with the four
subunits of the elongation factor, EF-1H, to form a
high-molecular-weight complex [26], relatively little is
known about the biological function of its yeast counter-
part. Our earlier studies suggested that the Ad of yeast
ValRS (residues 1~98) possesses non-specific tRNA-
binding activity (with a Kd of ~2 μM) that significantly
contributes to tRNA binding and aminoacylation activ-
ities of the enzyme [30,31]. We report herein that the
N-terminal domain (residues 1~135) of yeast ValRS can
act as an AD when fused to a sequence-specific DBD,
and this transcriptional activity is mainly attributable to
a tryptophan-rich peptide (WYDWW) within the N
domain. Using this pentapeptide as a reference struc-
ture, a much more active peptide, heptatryptophan
(W7), was consequently devised. Furthermore, W7 sti-
mulated transcription initiation via interaction with
TFIIB, a general transcription factor. It is our hope that
information obtained in this study will advance our
understanding of the biochemical properties of ADs in
general, and also provide new insights into the mechan-
isms of transcription activation in particular.
Results
Identification of an activation peptide
In addition to tRNA binding, we wondered whether the
N-terminal domain of yeast ValRS possesses another
function. To explore this possibility, the N-terminal
domain (residues 1~135) was cloned by fusion to the
DNA-binding protein, LexA, and used as bait to screen
a yeast library for interacting partners. Note that the
N-terminal sequence used in this assay was 37 residues
longer than the Ad (residues 1~98) used in previous
studies [30,31] to ensure that all of the sequence ele-
ments that might be important for interactions were
included. After all, the exact length of the Ad has yet to
be clearly defined. The DNA sequence encoding the N-
terminal domain was PCR-amplified and cloned as a
lexA fusion into pGilda (carrying an HIS3 marker) as
described in “Materials and Methods”, and the resulting
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construct was cotransformed with the reporter plasmid,
p8oplacZ (carrying a URA3 marker), into the EGY48
yeast strain. To rule out the possibility that the bait
hybrid protein was itself an autoactivator, the cotrans-
formants were first tested on selection medium (mini-
mal medium containing X-gal but lacking uracil,
histidine, and leucine) in the absence of any prey hybrid
protein. Unexpectedly, the LexA-N domain fusion by
itself could turn on the LEU2 and lacZ reporter genes;
the cotransformants grew robustly on the X-gal agar
plate and turned blue (Figure 1A, number 3). This result
suggests that the bait hybrid protein per se is a tran-
scription activator, and the N domain of yeast ValRS
acts as an AD.
It was noted that the operator sequences in the repor-
ter genes LEU2 and lacZ were not identical, and only
fusions that could turn on both reporter genes were
considered positive in this assay. To determine which
segment of the N domain actually accounted for this
transcriptional activity, various segments of the domain
were individually fused to LexA, and their transcrip-
tional activities were tested. As shown in Figure 1A, seg-
ments containing residues 98~115, 101~115, 104~115,
107~115, and 111~115 were active in the transcriptional
assay (numbers 4~8). In contrast, segments consisting of
residues 113~115, 98~112, and 98~109 had no detect-
able activity (numbers 9~11). Thus, the segment con-
taining residues 111~115 (WYDWW) is essential and
sufficient for this activity (number 8).
Quantitative assays of the b-gal activity (encoded by
the reporter gene carried on p8oplacZ) further showed
that among these active peptides, the segments contain-
ing residues 98~115, 101~115, and 104~115 had the
highest activities (~1.5-fold relative to that of the posi-
tive control); the segment containing residues 107~115
had medium activity (~0.8-fold relative to that of the
positive control); and the segments containing residues
1~135 and 111~115 had the lowest activities (~0.5-fold
relative to that of the positive control) (Figure 1B). As
expected, functionally inactive peptides had no detect-
able b-gal activity in the assays (Figure 1B, numbers
9~11). To check whether all of these LexA fusion con-
structs were properly expressed in the reporter yeast
strain, the expression profiles of these constructs were
analyzed by Western blotting using an anti-LexA anti-
body. As shown in Figure 1C, all of the LexA fusion
proteins were stably expressed by the constructs, with
only minor variations in protein levels, suggesting that
the negative phenotype observed on the X-gal plate for
the functionally inactive peptides was not caused by
severe protein degradation or insufficient protein synth-
esis (Figure 1A, numbers 9~11). pLexA-Pos (Gal4 fused
to LexA) and pGilda respectively served as positive and
negative controls in the assays.
Repetition of the pentapeptide sequence enhanced
activity
While the pentapeptide, WYDWW, can function as an
AD, its activity was relatively low, only ~50% of that of
the positive control and ~30% of that of the segment
containing residues 98~115 of the N domain (Figure 1B,
numbers 1, 4, and 8). To enhance its activity, two or
three tandem repeats of the pentapeptide sequence were
cloned, and the activities of the resulting constructs
were tested. As shown in Figure 2A and 2B, duplication
of the pentapeptide, resulting in (WYDWW)2, strongly
enhanced the activity (~3-fold increase relative to that
of a single pentapeptide) (compare numbers 3 and 4).
However, an additional replication of the sequence,
resulting in (WYDWW)3, did not further enhance the
activity; (WYDWW)3 exhibited activity comparable to
that of (WYDWW)2 (compare numbers 4 and 5). Wes-
tern blotting assays showed that these constructs
expressed similar levels of LexA fusion proteins. Thus,
changes in the transcriptional activity of these fusion
constructs did not result from different protein expres-
sion levels (Figure 2C, numbers 3~5).
W5 had activity higher than that of WYDWW
To examine which amino acid residues of the pentapep-
tide are critical for its activity, the residues were
mutated to alanine residues, and the activities of the
resulting constructs were tested. As shown in Figure 3,
mutation of the first two amino acid residues (WY) to
AA, the last two residues (WW) to AA, or the middle
residue (D) to A or K drastically reduced the activities
(compare numbers 3, 4, 5, 6, and 8). In contrast, muta-
tion of the middle residue (D) to W had little effect on
the activity (compare numbers 3 and 7). Moreover,
mutation of the second residue (Y) to W significantly
enhanced the activity (~1.8-fold) (compare numbers 3
and 9). Thus, it appears that W is preferred in all posi-
tions of the pentapeptide for activity. A Western blot
analysis showed that these mutations had only minor
effects on the expression levels of the fusion proteins
(Figure 3C).
To gain further insights, both of the non-W residues
in the pentapeptide were mutated to W residues (result-
ing in W5), and the activity of the resulting construct
was tested. As expected, W5 had an activity ~1.8-fold
higher than that of the native pentapeptide (Figure 4A,
B, numbers 3 and 4). Most amazingly, inserting two
more W residues into W5, yielding W7, further
enhanced the activity (~1.8-fold) (compare numbers 4
and 5). That is, the activity of W7 was ~3-fold higher
than that of the native pentapeptide (compare number 3
and 5). However, the activity of W9 was almost equiva-
lent to that of W5 (numbers 4 and 6). Thus, W7
appeared to be the strongest AD among those tested.
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Figure 1 Assays of the transcriptional activity of the N domain of yeast valyl-tRNA synthetase. (A) Transcriptional assays. Various
segments of the N domain of yeast ValRS were expressed as fusions to the specific DNA-binding protein, LexA, and the abilities of the resulting
fusions to turn on the reporter genes (LEU2 and lacZ) which are controlled by distinct LexA-responsive promoters were tested. Activation of the
reporter genes was indicated by the ability of the transformants to grow on selection medium lacking histidine, uracil, and leucine and to turn
blue. (B) Quantitative assays of b-gal activity. (C) Western blot analysis of the expressions of LexA fusion proteins. Upper panel, LexA fusion
protein; lower panel, phosphoglycerate kinase (PGK) (as a loading control). The numbers (circled) in A, B, and C represent the constructs shown
in A.
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To investigate whether the transcriptional activities of
these peptides were attributable to their hydrophobic
property, W7 was mutated to F7, and the activity of the
resulting construct was tested. As shown in Figure 4A
and 4B, changing W7 to F7 resulted in a functionally
inactive peptide that failed to turn on the reporter genes
(numbers 5 and 7). With respect to protein expression,
these fusion constructs expressed considerably different
levels of proteins. LexA-W5 and LexA-W9 produced the
highest protein expression levels (Figure 4C, numbers 4
and 6); LexA-WYDWW and LexA-W7 had medium
protein expression levels (numbers 3 and 5); and LexA-
F7 had the lowest protein expression level (number 7).
To further investigate whether the different protein
expression levels observed herein were caused by differ-
ent protein stabilities in vivo, a cycloheximide-chase
assay (or degradation assay) was carried out on
the representative constructs, LexA-WYDWW, LexA-
W7, and LexA-F7. To exclude the interference of tran-
scription activation, the host cell used for the assay was
INVSc1, instead of the reporter yeast strain, EGY48. As
shown in Figure 4E, these fusion proteins had conspicu-
ously distinct turnover rates. LexA-WYDWW was much
more stable than LexA-W7, and LexA-W7 was much
more stable than LexA-F7. LexA-F7 had a short half-life
(of <15 min) and was degraded in vivo at a much faster
speed than the other two fusion proteins tested. It
remains to be seen whether this attribute actually
accounted for the negative phenotype of LexA-F7 in the
transcriptional assay (Figure 4A, B). Another interesting
finding was the discovery that while LexA-W7 had the
highest transcriptional activity among these three con-
structs, it did not have the highest protein stability or
expression level (Figure 4, numbers 3, 5, and 7). Thus, it
appears that there were no direct correlations between
transcriptional activity and protein expression levels in
these instances. Figure 4D shows that similar levels of
cDNA products were generated from these fusion con-
structs, suggesting that the sequences encoding
WYDWW, W7, and F7 did not compromise the stability
of the specific lexA mRNAs in vivo.
W7 is a non-promoter-specific AD
We next tested whether the transcriptional activities of
W7 and (WYDWW)2 were promoter-specific, and
whether they were affected by the DBD used. To this
end, W7 and (WYDWW)2 were assayed in a Gal4-based
system, where the AD was fused in-frame to the Gal4-
DBD cloned in pGBKT7 (which carries a TRP1 marker),
and the reporter genes used were HIS3 and MEL1
(which encodes a-galactosidase) under the control of
two completely heterologous Gal4-responsive upstream
activating sequences and promoter elements, GAL1 and
MEL1, respectively. As shown in Figure 5, both Gal4-
Figure 2 Assays of the transcriptional activities of the pentapeptide and its tandem repeats. (A) Transcriptional assays. The pentapeptide,
WYDWW, and its tandem repeats were expressed as fusions to the specific DNA-binding protein, LexA, and the abilities of the resulting fusion
proteins to turn on the reporter genes (LEU2 and lacZ), which are controlled by distinct LexA-responsive promoters, were tested. (B) Quantitative
assays of b-gal activity. (C) Western blot analysis of the expressions of LexA fusion proteins. Upper panel, LexA fusion protein; lower panel, PGK (as
a loading control). The numbers (circled) in A, B, and C represent the constructs shown in A.
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DBD fusion proteins turned on the reporter genes;
transformants carrying either of these two fusion con-
structs (Gal4-DBD-W7 or Gal4-DBD-(WYDWW)2) grew
robustly and turned blue on selection medium contain-
ing X-a-gal but lacking tryptophan and histidine (Figure
5A, numbers 3 and 4), suggesting that both of these
peptides acted as ADs in Gal4-DBD fusion proteins.
Thus, the transcriptional activities of these two peptides
were non-promoter-specific and were operational in
both LexA- and Gal4-DBD-responsive reporter genes.
Quantitatively, these two fusion proteins had tran-
scriptional activities ~2.5-fold lower than that of the
positive control (Figure 5B, numbers 1, 3, and 4). This
is not surprising, considering the fact that the positive
control was a wild-type GAL4 gene. Western blot
assays showed that these two Gal4-DBD fusion con-
structs had protein expression levels much lower than
that of the Gal4-DBD alone (Figure 5C, numbers 2~4).
Whether the ADs destabilized the Gal4-DBD fusion
proteins and whether the relatively poor transcriptional
activity of these two fusion constructss was caused by
a lower level of protein expression are yet to be deter-
mined. However, regardless of the diverse protein
expression levels, these results clearly demonstrate the
ability of these two peptides to function as ADs in the
Gal4-based system.
W7 acts as an AD in a two-hybrid system
So far, we have shown that W7 and (WYDWW)2 can
act as ADs when directly fused to a sequence-specific
DBD such as LexA and Gal4-DBD (Figures 2, 4, 5). The
question arose as to whether these two short peptides
can act as efficiently when they are physically separated
from the DBD. To answer this question, DNA
sequences encoding these two peptides were individually
cloned into pGADT7-T (a prey fusion vector encoding
the Gal4-AD-T fusion protein) to replace the sequence
encoding the Gal4-AD, and the transcriptional activities
of the resulting constructs were tested following the
protocols devised for the yeast two-hybrid system. As
shown in Figure 6, murine p53 (as a part of the Gal4-
DBD-53 fusion) specifically interacted with the SV40
large T-antigen (as a part of the Gal4-AD-T fusion) and
turned on the reporter genes, HIS3 and MEL1 (number
1, serving as the positive control). In contrast, human
lamin C (as a part of the Gal4-DBD-Lam fusion) did not
Figure 3 Assays of the transcriptional activities of native and mutant pentapeptides. (A) Transcriptional assays. Native and mutant
pentapeptides were expressed as fusions to the specific DNA-binding protein, LexA, and the abilities of the resulting fusion proteins to turn on
the reporter genes (LEU2 and lacZ), which are controlled by distinct LexA-responsive promoters, were tested. (B) Quantitative assays of b-gal
activity. (C) Western blot analysis of the expressions of LexA fusion proteins. Upper panel, LexA fusion protein; lower panel, phosphoglycerate
kinase (PGK) (as a loading control). The numbers (circled) in A, B, and C represent the constructs shown in A.
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interact with the large T-antigen and therefore failed to
turn on the reporter genes (number 2, serving as the
negative control). Interestingly, both W7-T and
(WYDWW)2-T fusions turned on the reporter genes
when acting in concert with the Gal4-DBD-53 fusion
(numbers 3 and 5), but failed to do so when acting in
concert with the Gal4-DBD-Lam fusion (numbers 4 and
6). This observation provides strong evidence that both
W7 and (WYDWW)2 can act as ADs in a traditional
two-hybrid system, albeit with efficiencies poorer than
that of Gal4-AD (Figure 6B, numbers 1, 3, and 5).
W7 mediates transcription activation through interacting
with TFIIB
To date, only a few protein factors have unambiguously
been identified as direct targets of transcriptional activa-
tors, including TBP, TFIIB, TFIIH, and a few others [6].
We wondered whether W7 also stimulates transcription
Figure 4 Assays of the transcriptional activities of W5, W7, and W9. (A) Transcriptional assays. W5, W7, and W9 were expressed as fusions to
the specific DNA-binding protein, LexA, and the abilities of the resulting fusion proteins to turn on the reporter genes (LEU2 and lacZ), which
are controlled by distinct LexA-responsive promoters, were tested. (B) Quantitative assays of b-gal activity. (C) Western blot analysis of the
expressions of LexA fusion proteins. (D) RT-PCR. Relative levels of specific lexA mRNAs generated from each construct were determined by RT-
PCR (28 cycles). Actin served as an internal control. “RNA control“ denotes no reverse transcription for RNA prepared from W7. (E) Degradation
assay. These constructs were expressed under the control of an inducible GAL1 promoter. Upper panel, LexA fusion protein; lower panel, PGK (as
a loading control). T0, T0.5, T1, T2, T4, and T8 mean 0, 0.5, 1, 2, 4, and 8 h post-induction, respectively. The numbers (circled) in A to E represent
the constructs shown in A.
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initiation through interaction with one of these protein
factors. Pursuant to this objective, TBP, TFIIB, and TFIIH
were individually cloned into pGilda (a bait fusion vector
encoding the LexA fusion protein), and then their interac-
tion with W7 (as a part of the B42-W7 fusion protein) was
tested using a yeast two-hybrid system. LexA and B42
respectively served as the DBD and AD in this assay. As
shown in Figure 7, all of these LexA fusion proteins were
well expressed in the test yeast strain EGY48 (Figure 7B),
with LexA-TFIIH having a lower expression level. In the
absence of W7, none of these fusion constructs per se
could simultaneously turn on the designated reporter
genes, LEU2 and lacZ (Figure 7A). However, in the pre-
sence of W7, TFIIB, but not TBP or TFIIH, could turn on
both reporter genes (Figure 7C). This result strongly sug-
gests that W7 specifically interacts with TFIIB.
Discussion
We report herein that the N-terminal domain of yeast
ValRS acts as an AD when fused to a sequence-specific
DBD, LexA (Figure 1). However, there is no direct evi-
dence so far showing that yeast ValRS actually functions
as a transcription activator in the nucleus. More experi-
ments are currently underway to validate this possibility.
Despite this uncertain aspect, a core sequence element
accounting for this activity was mapped to a region near
the C-terminus of the N domain. This core sequence
element contains only five amino acid residues:
WYDWW (N-terminal residues 111~115) (Figure 1).
Interestingly, the core sequence element per se retained
much of the transcriptional activity and could be stably
expressed as a fusion to the DBD in yeast (Figure 1). A
mutagenesis study indicated that W residues in the pen-
tapeptide were crucial for its activity. Even the Y resi-
due, which also possesses an aromatic ring in its side
chain, was not as supportive of the activity as were the
W residues (Figure 3). As a result, the native pentapep-
tide acted less efficiently (~1.8-fold) than did
WWDWW and WWWWW as an AD (Figures 3, 4).
Using this core sequence element as a reference, a
much-stronger activation peptide, W7, was successfully
produced. W7 had ~3-fold higher transcriptional activity
than those of the native pentapeptide and the N domain
(Figures 1, 4). While we cannot rule out the possibility
that W7 somehow altered the affinity or specificity for
the lexA operators of the LexA fusion protein, W7 has
to be capable of interacting with one of the components
of the transcription apparatus to stimulate transcription
of the reporter genes. To our knowledge, W7 is so far
the smallest AD that retains strong transcriptional activ-
ity. With its small size, W7 is unlikely to interfere with
the folding of fused proteins or to occlude the normal
Figure 5 Assays of the transcriptional activity of W7 using the Gal4-based system. (A) Transcriptional assays. W7 and (WYDWW)2 were
expressed as fusions to the Gal4-DBD, and the abilities of the resulting fusion proteins to turn on the reporter genes (HIS3 and MEL1), which are
controlled by distinct Gal4-responsive promoters, were tested. (B) Quantitative assays of b-gal activity. (C) Western blot analysis of the
expressions of Gal4-DBD fusion proteins. Upper panel, LexA fusion protein; lower panel, PGK (as a loading control). The numbers (circled) in A, B,
and C denote the constructs shown in A.
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site of interaction. In addition, W7 can significantly
reduce the overall size of the prey fusion construct, and
therefore has the potential to enhance the efficiency of
plasmid transformation, which is a long-standing issue
when screening a large library for novel interacting part-
ners. Similar to the reasons that the His6 tag is widely
accepted and used for protein purification, W7 may be
an excellent replacement for the Gal4-AD or B42 in
two-hybrid screening as an AD.
A preliminary study suggested that the direct target of
W7 may be the general transcription factor, TFIIB (Figure
7), which was previously shown to be one of the interact-
ing partners of the acidic transcription activator, Gal4
[10]. It is believed that recruitment of TFIIB and others
by Gal4 leads to assembly of the transcription apparatus
at the promoter site and subsequent transcription initia-
tion [7]. However, sequence alignment between these
two ADs (Gal4-AD and W7) showed little sequence
homology. Thus, Gal4-AD and W7 may interact with dif-
ferent sites of TFIIB or through a different mechanism.
Alternatively, a certain portion of Gal4 may fold into a
three-dimensional structure that displays a hydrophobic
feature similar to that of W7. In any case, it is interesting
to find that both of these ADs mediate transcription acti-
vation through interacting with TFIIB. Thus, the minute
AD, W7, might turn out to be an interesting paradigm
for further mechanistic studies of transcription activation.
Conclusions
A short peptide containing seven consecutive trypto-
phan residues (W7) can function as an activation
domain when fused to a DNA-binding protein, LexA,
and turn on reporter genes with distinct LexA-respon-
sive promoters. Like the activation domain of Gal4, W7
mediates transcription activation through interacting
with the general transcription factor, TFIIB.
Methods
Construction of various LexA and Gal4-DBD fusion
constructs
To clone the DNA sequence encoding the N domain of
yeast ValRS (base pairs +1 to +405) into pGilda and
Figure 6 Assays of the transcriptional activity of W7 using a two-hybrid system. (A) Two-hybrid assays. W7 and (WYDWW)2 were expressed
as fusions to the SV40 large T-antigen, and the abilities of the resulting fusions to specifically interact with Gal4-DBD-53 and turn on the reporter
genes (HIS3 and MEL1) were tested. For clarity, the bait and prey fusion proteins encoded by the constructs are depicted in parentheses
following the vector names. (B) Quantitative assays of b-gal activity. The numbers (circled) in A and B represent the constructs shown in A.
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pGBKT7 (BD Biosciences Clontech, Palo Alto, CA) for
the transcriptional assays, a set of primers complemen-
tary to nucleotides -15 to +15 and +390 to +420 of
VAS1 were respectively used to amplify the DNA frag-
ment using a plasmid-borne VAS1 gene as a template.
The forward primer contained an EcoRI site, and the
reverse primer contained an XhoI site. The 405-bp PCR
fragment was first digested with EcoRI and XhoI and
then cloned into appropriate sites in pGilda or pGBKT7.
To clone shorter fragments of the N domain, such as
those coding for amino acid residues 98~115 and
111~115, or their derivatives, such as those coding for
W5, W7, and W9, into these two vectors, a pair of com-
plementary oligonucleotides coding for the desired
sequences were annealed and then cloned into the
EcoRI-XhoI sites of these vectors. Sequences of the
cloned DNA fragments were verified by DNA
sequencing.
Transcriptional assay
This assay essentially followed the protocol of a yeast
two-hybrid assay provided by the manufacturer (BD
Biosciences Clontech), except that the prey cloned in
pB42AD was not used. Briefly, the gene of interest was
first cloned as a lexA fusion into pGilda (carrying an
HIS3 marker) as mentioned above. The lexA fusion con-
struct was then co-transformed with the reporter plas-
mid, p8oplacZ (carrying a URA3 marker and a lacZ
reporter gene under the control of eight copies of the
LexA operator and the minimal GAL1 promoter), into
the EGY48 yeast strain (carrying an LEU2 reporter gene
under the control of six copies of the LexA operator
and the minimal LEU2 promoter), and the resulting
cotransformants were selected on minimal medium
lacking uracil and histidine. A single colony of the
cotransformants that grew on the selection medium was
picked and streaked on an agar plate containing X-gal
Figure 7 Identification of the interacting partners of W7 using a two-hybrid system. (A) Transcriptional assay. TBP, TFIIB, and TFIIH were
expressed as fusions to LexA, and the abilities of the resulting fusions to turn on the reporter genes (LEU2 and lacZ) were tested. (B) Western
blot analysis of the expressions of LexA fusion proteins. Upper panel, LexA fusion protein; lower panel, PGK (as a loading control). The numbers
(circled) in A and B denote the constructs shown in A. (C) Two-hybrid assays. TBP, TFIIB, and TFIIH were expressed as fusions to LexA, and the
abilities of the resulting fusions to specifically interact with W7 and turn on the reporter genes (LEU2 and lacZ) were tested. For clarity, the bait
and prey fusion proteins encoded by the constructs are depicted in parentheses following the vector names.
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but lacking uracil, histidine, and leucine. The streaked
colony could not grow on the X-gal plate and turn blue
unless the LexA fusion protein had turned on both
reporter genes (LEU2 and lacZ). Note that the DNA-
binding protein, LexA, alone could not activate tran-
scription of the LexA-responsive reporter genes, but
could do so when fused to an AD.
Alternatively, the transcriptional activity of the N
domain was tested using a Gal4-based system (BD Bios-
ciences Clontech), in which the DNA sequence encod-
ing the N domain was fused in-frame to the sequence
encoding Gal4-DBD cloned in pGBKT7 (carrying a
TRP1 marker), and the resulting construct was then
transformed into the AH109 reporter yeast strain and
tested for its ability to turn on the reporter genes, HIS3
and MEL1. HIS3 was under the control of the GAL1
upstream activating sequence and a minimal promoter
containing the GAL1 TATA box. The expression of
MEL1 was controlled by the intact MEL1 promoter,
including the MEL1 upstream activating sequence and
MEL1 minimal promoter. The transformants could not
grow and turn blue on selection medium containing X-
a-gal but lacking tryptophan and histidine unless the
Gal4-DBD fusion protein had turned on both reporter
genes.
Western blot analysis
Protein expression patterns of the LexA fusions were
determined by a chemiluminescence-based Western blot
analysis. The transformants used in the transcriptional
assays were grown in selection medium lacking uracil
and histidine. Total protein extracts were prepared from
the transformants with a buffer containing 50 mM Tris
(pH 7.4), 150 mM NaCl, 0.5% sodium dodecylsulfate
(SDS), 0.5% Triton X-100, 10 mM ethylenediaminete-
traacetic acid, and 1 mM phenylmethanesulfonyl fluor-
ide. Aliquots of the protein extracts (~40 μg) were
loaded onto a mini gel (8 × 10 cm) containing 10%
polyacrylamide and electrophoresed at 100 V for ~2 h.
Following electrophoresis, the resolved proteins were
transferred to a polyvinylidene difluoride (PVDF) mem-
brane using a semi-dry transfer device. The membrane
was probed with a horseradish peroxidase (HRP)-conju-
gated anti-LexA antibody (Invitrogen, Carlsbad, CA) and
then exposed to x-ray film following the addition of
appropriate substrates. The protein expression patterns
of the Gal4-DBD fusions were determined following a
similar protocol.
b-Galactosidase (b-Gal) assay
Yeast cells were pelleted by centrifugation at 12,000 × g
for 30 s and resuspended in 100 μl of breaking buffer
(100 mM Tris-HCl (pH 8.0), 1 mM dithiothreitol, 10%
glycerol, and 2 mM phenylmethanesulfonyl fluoride)
and 100 μl of beads. Cells were then lysed at 4°C using
a bead beater, followed by centrifugation at 12,000 × g
for 2 min. Aliquots of the supernatants (25~250 μg)
were diluted to 0.8 ml with Z buffer (60 mM Na2HPO4,
40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, and 50
mM 2-mercaptoethanol). b-Gal activity assays were
initiated (at 37°C) by adding 0.2 ml of o-nitrophenyl b-
D-galactoside (4 mg/ml). The reaction mixtures were
incubated with constant shaking at 37°C for 20 min and
then terminated by the addition of 0.4 ml of 1 M
Na2CO3. The reaction mixtures were centrifuged at
12,000 × g for 2 min, and the absorbance (A420) of the
supernatants was determined. Relative b-gal activities
were calculated from A420 readings normalized to pro-
tein concentrations. Data were obtained from three
independent experiments and averaged. Error bars indi-
cate (± 2 × standard deviation).
Reverse-transcription (RT)-PCR
To determine the relative levels of specific lexA mRNAs
derived from the fusion constructs, a semiquantitative RT-
PCR experiment was carried out following the protocols
provided by the manufacturer (Invitrogen). Total RNA was
first isolated from the transformants and then treated with
DNase to remove contaminating DNA. Aliquots of RNA
(~1 μg) were then reverse-transcribed into single-stranded
complementary (c)DNA using an oligo-dT primer. After
RNase H treatment, the single-stranded cDNA products
were amplified by a PCR using a pair of specific primers.
The forward and reverse primers respectively contained
sequences complementary to nucleotides +1 to +21 (5’-
ATGAAAGCGTTAACGGCCAGG-3’) and nucleotides
+370 to +390 of lexA (5’-CAAGTCACCATCCA-
TAATGCC-3’). As a control, the relative levels of actin-
specific mRNAs in each preparation were also determined
using a set of primers complementary to nucleotides +537
to +560 (5’-ACCAACTGGGACGATATGGAAAAG-3’)
and nucleotides +696 to +719 (5’-TTGGATGGAAACG-
TAGAAGGCTGG-3’) of actin, respectively.
Degradation assay
To determine the turnover of the fusion proteins, analo-
gous lexA fusion constructs that were expressed under
the control of an inducible GAL1 promoter were trans-
formed into INVSc1. Transformants carrying these con-
structs were first grown in medium lacking histidine
with 2% raffinose to a cell density of ~1.0 A600 and then
induced with 2% galactose for 1 h. Afterward, cells were
washed twice and then grown in medium containing 2%
glucose and 100 μg/ml cycloheximide but lacking histi-
dine. Cells were harvested at 0, 0.5, 1, 2, 4, and 8 h post-
induction and lysed. Forty-microgram samples of the
cellular lysates were resolved on 10% polyacrylamide
and electrophoresed at 100 V for ~1 h, and the proteins
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were transferred to a PVDF membrane and immuno-
blotted with an HRP-conjugated anti-LexA antibody.
Acknowledgements
This work was supported by a grant (NSC97-2311-B-008-003-MY3 to C.C.W.)
from the National Science Council (Taipei, Taiwan). We wish to thank Prof.
Shen-Liang Chen (National Central University, Jung-li, Taiwan) for helpful
suggestions on the manuscript.
Authors’ contributions
CHL generated the various lexA constructs and performed the RT-PCR,
Western blotting, and transcriptional assays. GL and CPC performed the
degradation and b-galactosidase assays. CCW coordinated the project and
wrote the manuscript. All authors read and approved the final manuscript.
Received: 17 July 2010 Accepted: 16 November 2010
Published: 16 November 2010
References
1. Kuras L, Struhl K: Binding of TBP to promoters in vivo is stimulated by
activators and requires Pol II holoenzyme. Nature 1999,
399(6736):609-613.
2. Ptashne M, Gann A: Genes & Signals. New York: USA: Cold Spring Harbor
Laboratory Press; 2002.
3. Sadowski I, Ma J, Triezenberg S, Ptashne M: GAL4-VP16 is an unusually
potent transcriptional activator. Nature 1988, 335(6190):563-564.
4. Courey AJ, Holtzman DA, Jackson SP, Tjian R: Synergistic activation by the
glutamine-rich domains of human transcription factor Sp1. Cell 1989,
59(5):827-836.
5. Mermod N, O’Neill EA, Kelly TJ, Tjian R: The proline-rich transcriptional
activator of CTF/NF-I is distinct from the replication and DNA binding
domain. Cell 1989, 58(4):741-753.
6. Green MR: Eukaryotic transcription activation: right on target. Mol Cell
2005, 18(4):399-402.
7. Traven A, Jelicic B, Sopta M: Yeast Gal4: a transcriptional paradigm
revisited. EMBO Rep 2006, 7(5):496-499.
8. Wu Y, Reece RJ, Ptashne M: Quantitation of putative activator-target
affinities predicts transcriptional activating potentials. EMBO J 1996,
15(15):3951-3963.
9. Carrozza MJ, John S, Sil AK, Hopper JE, Workman JL: Gal80 confers
specificity on HAT complex interactions with activators. J Biol Chem 2002,
277(27):24648-24652.
10. Zenke FT, Engles R, Vollenbroich V, Meyer J, Hollenberg CP, Breunig KD:
Activation of Gal4p by galactose-dependent interaction of galactokinase
and Gal80p. Science 1996, 272(5268):1662-1665.
11. Carter CW Jr: Cognition, mechanism, and evolutionary relationships in
aminoacyl-tRNA synthetases. Annu Rev Biochem 1993, 62:715-748.
12. Martinis SA, Schimmel P: Escherichia coli and Salmonella Cellular and
Molecular Biology. Am. Soc. Microbiol., Washington, DC;, 2 1996.
13. Giege R, Sissler M, Florentz C: Universal rules and idiosyncratic features in
tRNA identity. Nucleic Acids Res 1998, 26(22):5017-5035.
14. Pelchat M, Lapointe J: Aminoacyl-tRNA synthetase genes of Bacillus
subtilis: organization and regulation. Biochem Cell Biol 1999, 77(4):343-347.
15. Maréchal-Drouard L, Weil JH, Dietrich A: Nuclear-encoded transfer RNAs in
plant mitochondria. Annu Rev Cell Biol 1993, 8:115-131.
16. Tang HL, Yeh LS, Chen NK, Ripmaster T, Schimmel P, Wang CC: Translation
of a yeast mitochondrial tRNA synthetase initiated at redundant non-
AUG codons. J Biol Chem 2004, 279(48):49656-49663.
17. Chang KJ, Wang CC: Translation initiation from a naturally occurring non-
AUG codon in Saccharomyces cerevisiae. J Biol Chem 2004,
279(14):13778-13785.
18. Natsoulis G, Hilger F, Fink GR: The HTS1 gene encodes both the
cytoplasmic and mitochondrial histidine tRNA synthetases of S.
cerevisiae. Cell 1986, 46(2):235-243.
19. Chatton B, Walter P, Ebel JP, Lacroute F, Fasiolo F: The yeast VAS1 gene
encodes both mitochondrial and cytoplasmic valyl-tRNA synthetases. J
Biol Chem 1988, 263(1):52-57.
20. Mirande M: Aminoacyl-tRNA synthetase family from prokaryotes and
eukaryotes: structural domains and their implications. Prog Nucleic Acid
Res Mol Biol 1991, 40:95-142.
21. Wang CC, Schimmel P: Species barrier to RNA recognition overcome with
nonspecific RNA binding domains. J Biol Chem 1999, 274(23):16508-16512.
22. Wang CC, Morales AJ, Schimmel P: Functional redundancy in the
nonspecific RNA binding domain of a class I tRNA synthetase. J Biol
Chem 2000, 275(22):17180-17186.
23. Kaminska M, Deniziak M, Kerjan P, Barciszewski J, Mirande M: A recurrent
general RNA binding domain appended to plant methionyl-tRNA
synthetase acts as a cis-acting cofactor for aminoacylation. EMBO J 2000,
19(24):6908-6917.
24. Francin M, Kaminska M, Kerjan P, Mirande M: The N-terminal domain of
mammalian Lysyl-tRNA synthetase is a functional tRNA-binding domain.
J Biol Chem 2002, 277(3):1762-1769.
25. Simos G, Segref A, Fasiolo F, Hellmuth K, Shevchenko A, Mann M, Hurt EC:
The yeast protein Arc1p binds to tRNA and functions as a cofactor for
the methionyl- and glutamyl-tRNA synthetases. EMBO J 1996,
15(19):5437-5448.
26. Negrutskii BS, Shalak VF, Kerjan P, El’skaya AV, Mirande M: Functional
interaction of mammalian valyl-tRNA synthetase with elongation factor
EF-1alpha in the complex with EF-1H. J Biol Chem 1999, 274(8):4545-4550.
27. Schimmel P, Wang CC: Getting tRNA synthetases into the nucleus. Trends
Biochem Sci 1999, 24(4):127-128.
28. Martinis SA, Plateau P, Cavarelli J, Florentz C: Aminoacyl-tRNA synthetases:
a family of expanding functions. Mittelwihr, France, October 10-15,
1999. EMBO J 1999, 18(17):4591-4596.
29. Francklyn C, Perona JJ, Puetz J, Hou YM: Aminoacyl-tRNA synthetases:
versatile players in the changing theater of translation. RNA 2002,
8(11):1363-1372.
30. Chang CP, Lin G, Chen SJ, Chiu WC, Chen WH, Wang CC: Promoting the
formation of an active synthetase/tRNA complex by a nonspecific tRNA-
binding domain. J Biol Chem 2008, 283(45):30699-30706.
31. Chiu WC, Chang CP, Wang CC: Evolutionary basis of converting a
bacterial tRNA synthetase into a yeast cytoplasmic or mitochondrial
enzyme. J Biol Chem 2009, 284(36):23954-23960.
doi:10.1186/1471-2199-11-85
Cite this article as: Lin et al.: A tryptophan-rich peptide acts as a
transcription activation domain. BMC Molecular Biology 2010 11:85.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Lin et al. BMC Molecular Biology 2010, 11:85
http://www.biomedcentral.com/1471-2199/11/85
Page 12 of 12
